nodes	percent_of_prediction	percent_of_DWPC	metapath
Ticlopidine—CYP3A4—bone cancer	0.39	1	CbGaD
Ticlopidine—MPO—Carboplatin—bone cancer	0.205	0.422	CbGbCtD
Ticlopidine—MPO—Cisplatin—bone cancer	0.175	0.36	CbGbCtD
Ticlopidine—CYP2B6—Cisplatin—bone cancer	0.0389	0.08	CbGbCtD
Ticlopidine—CYP2B6—Doxorubicin—bone cancer	0.0261	0.0536	CbGbCtD
Ticlopidine—CYP2C9—Cisplatin—bone cancer	0.0205	0.0423	CbGbCtD
Ticlopidine—CYP2D6—Doxorubicin—bone cancer	0.0126	0.0259	CbGbCtD
Ticlopidine—CYP3A4—Doxorubicin—bone cancer	0.008	0.0165	CbGbCtD
Ticlopidine—Clopidogrel—CYP3A4—bone cancer	0.00233	1	CrCbGaD
Ticlopidine—Alveolitis allergic—Methotrexate—bone cancer	0.0018	0.0304	CcSEcCtD
Ticlopidine—Leukaemia—Methotrexate—bone cancer	0.00174	0.0295	CcSEcCtD
Ticlopidine—Diarrhoea haemorrhagic—Epirubicin—bone cancer	0.00174	0.0294	CcSEcCtD
Ticlopidine—Leukaemia—Epirubicin—bone cancer	0.00163	0.0276	CcSEcCtD
Ticlopidine—Diarrhoea haemorrhagic—Doxorubicin—bone cancer	0.00161	0.0272	CcSEcCtD
Ticlopidine—Leukaemia—Doxorubicin—bone cancer	0.00151	0.0256	CcSEcCtD
Ticlopidine—Nephropathy—Methotrexate—bone cancer	0.000986	0.0167	CcSEcCtD
Ticlopidine—Myositis—Epirubicin—bone cancer	0.000896	0.0152	CcSEcCtD
Ticlopidine—Pain—Carboplatin—bone cancer	0.00089	0.0151	CcSEcCtD
Ticlopidine—Myositis—Doxorubicin—bone cancer	0.000829	0.014	CcSEcCtD
Ticlopidine—Body temperature increased—Carboplatin—bone cancer	0.000822	0.0139	CcSEcCtD
Ticlopidine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000713	0.0114	CbGpPWpGaD
Ticlopidine—Thrombocytosis—Epirubicin—bone cancer	0.000706	0.012	CcSEcCtD
Ticlopidine—Bone marrow depression—Methotrexate—bone cancer	0.000695	0.0118	CcSEcCtD
Ticlopidine—Haemolytic anaemia—Cisplatin—bone cancer	0.000688	0.0116	CcSEcCtD
Ticlopidine—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000684	0.0109	CbGpPWpGaD
Ticlopidine—Lung disorder—Methotrexate—bone cancer	0.000663	0.0112	CcSEcCtD
Ticlopidine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000654	0.0104	CbGpPWpGaD
Ticlopidine—Thrombocytosis—Doxorubicin—bone cancer	0.000654	0.0111	CcSEcCtD
Ticlopidine—Bone marrow depression—Epirubicin—bone cancer	0.000651	0.011	CcSEcCtD
Ticlopidine—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000645	0.0103	CbGpPWpGaD
Ticlopidine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000641	0.0102	CbGpPWpGaD
Ticlopidine—Hyponatraemia—Cisplatin—bone cancer	0.000623	0.0106	CcSEcCtD
Ticlopidine—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.000621	0.0105	CcSEcCtD
Ticlopidine—Lung disorder—Epirubicin—bone cancer	0.000621	0.0105	CcSEcCtD
Ticlopidine—Bone marrow depression—Doxorubicin—bone cancer	0.000602	0.0102	CcSEcCtD
Ticlopidine—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000587	0.00935	CbGpPWpGaD
Ticlopidine—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000584	0.0093	CbGpPWpGaD
Ticlopidine—Lung disorder—Doxorubicin—bone cancer	0.000574	0.00972	CcSEcCtD
Ticlopidine—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000572	0.00911	CbGpPWpGaD
Ticlopidine—Cramp muscle—Cisplatin—bone cancer	0.000559	0.00947	CcSEcCtD
Ticlopidine—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000551	0.00876	CbGpPWpGaD
Ticlopidine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00055	0.00876	CbGpPWpGaD
Ticlopidine—P2RY12—G alpha (i) signalling events—RGS1—bone cancer	0.000545	0.00868	CbGpPWpGaD
Ticlopidine—P2RY12—G alpha (i) signalling events—GRM4—bone cancer	0.000545	0.00868	CbGpPWpGaD
Ticlopidine—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.00054	0.00859	CbGpPWpGaD
Ticlopidine—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000521	0.0083	CbGpPWpGaD
Ticlopidine—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000519	0.00826	CbGpPWpGaD
Ticlopidine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000518	0.00824	CbGpPWpGaD
Ticlopidine—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000511	0.00813	CbGpPWpGaD
Ticlopidine—Pancytopenia—Cisplatin—bone cancer	0.00051	0.00863	CcSEcCtD
Ticlopidine—Jaundice cholestatic—Epirubicin—bone cancer	0.0005	0.00846	CcSEcCtD
Ticlopidine—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000495	0.00788	CbGpPWpGaD
Ticlopidine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000486	0.00773	CbGpPWpGaD
Ticlopidine—Arthropathy—Epirubicin—bone cancer	0.000483	0.00818	CcSEcCtD
Ticlopidine—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000481	0.00766	CbGpPWpGaD
Ticlopidine—Vasculitis—Methotrexate—bone cancer	0.000481	0.00814	CcSEcCtD
Ticlopidine—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000476	0.00757	CbGpPWpGaD
Ticlopidine—Renal failure—Cisplatin—bone cancer	0.00047	0.00796	CcSEcCtD
Ticlopidine—Neuropathy peripheral—Cisplatin—bone cancer	0.000469	0.00794	CcSEcCtD
Ticlopidine—Jaundice cholestatic—Doxorubicin—bone cancer	0.000463	0.00783	CcSEcCtD
Ticlopidine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000451	0.00718	CbGpPWpGaD
Ticlopidine—Arthropathy—Doxorubicin—bone cancer	0.000447	0.00757	CcSEcCtD
Ticlopidine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000442	0.00703	CbGpPWpGaD
Ticlopidine—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000441	0.00702	CbGpPWpGaD
Ticlopidine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000425	0.00676	CbGpPWpGaD
Ticlopidine—Ecchymosis—Methotrexate—bone cancer	0.000424	0.00719	CcSEcCtD
Ticlopidine—Colitis—Epirubicin—bone cancer	0.000422	0.00714	CcSEcCtD
Ticlopidine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000411	0.00655	CbGpPWpGaD
Ticlopidine—Sepsis—Methotrexate—bone cancer	0.000407	0.0069	CcSEcCtD
Ticlopidine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000406	0.00647	CbGpPWpGaD
Ticlopidine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000403	0.00641	CbGpPWpGaD
Ticlopidine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000401	0.00639	CbGpPWpGaD
Ticlopidine—Tinnitus—Cisplatin—bone cancer	0.0004	0.00678	CcSEcCtD
Ticlopidine—Ecchymosis—Epirubicin—bone cancer	0.000397	0.00672	CcSEcCtD
Ticlopidine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000394	0.00627	CbGpPWpGaD
Ticlopidine—Diabetes mellitus—Methotrexate—bone cancer	0.000392	0.00663	CcSEcCtD
Ticlopidine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000391	0.00622	CbGpPWpGaD
Ticlopidine—Colitis—Doxorubicin—bone cancer	0.00039	0.00661	CcSEcCtD
Ticlopidine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000387	0.00616	CbGpPWpGaD
Ticlopidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000385	0.00613	CbGpPWpGaD
Ticlopidine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000382	0.00608	CbGpPWpGaD
Ticlopidine—Sepsis—Epirubicin—bone cancer	0.000381	0.00645	CcSEcCtD
Ticlopidine—Hepatic failure—Methotrexate—bone cancer	0.000379	0.00642	CcSEcCtD
Ticlopidine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000374	0.00596	CbGpPWpGaD
Ticlopidine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000374	0.00596	CbGpPWpGaD
Ticlopidine—Flatulence—Cisplatin—bone cancer	0.000368	0.00624	CcSEcCtD
Ticlopidine—Ecchymosis—Doxorubicin—bone cancer	0.000367	0.00622	CcSEcCtD
Ticlopidine—Diabetes mellitus—Epirubicin—bone cancer	0.000367	0.00621	CcSEcCtD
Ticlopidine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000362	0.00577	CbGpPWpGaD
Ticlopidine—Dermatitis exfoliative—Methotrexate—bone cancer	0.000361	0.00611	CcSEcCtD
Ticlopidine—Muscle spasms—Cisplatin—bone cancer	0.00036	0.00609	CcSEcCtD
Ticlopidine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000359	0.00572	CbGpPWpGaD
Ticlopidine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000359	0.00571	CbGpPWpGaD
Ticlopidine—Vascular purpura—Epirubicin—bone cancer	0.000356	0.00604	CcSEcCtD
Ticlopidine—Hepatic failure—Epirubicin—bone cancer	0.000355	0.00601	CcSEcCtD
Ticlopidine—Sepsis—Doxorubicin—bone cancer	0.000353	0.00597	CcSEcCtD
Ticlopidine—P2RY12—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.00035	0.00557	CbGpPWpGaD
Ticlopidine—MPO—C-MYB transcription factor network—KIT—bone cancer	0.000347	0.00552	CbGpPWpGaD
Ticlopidine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000344	0.00548	CbGpPWpGaD
Ticlopidine—Osteoarthritis—Methotrexate—bone cancer	0.000341	0.00577	CcSEcCtD
Ticlopidine—Diabetes mellitus—Doxorubicin—bone cancer	0.000339	0.00574	CcSEcCtD
Ticlopidine—Dermatitis exfoliative—Epirubicin—bone cancer	0.000338	0.00572	CcSEcCtD
Ticlopidine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000331	0.00527	CbGpPWpGaD
Ticlopidine—Purpura—Epirubicin—bone cancer	0.000331	0.0056	CcSEcCtD
Ticlopidine—P2RY12—GPCR ligand binding—GRM4—bone cancer	0.00033	0.00525	CbGpPWpGaD
Ticlopidine—Vascular purpura—Doxorubicin—bone cancer	0.00033	0.00558	CcSEcCtD
Ticlopidine—Hepatic failure—Doxorubicin—bone cancer	0.000328	0.00556	CcSEcCtD
Ticlopidine—Hyponatraemia—Epirubicin—bone cancer	0.00032	0.00542	CcSEcCtD
Ticlopidine—P2RY12—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00032	0.00509	CbGpPWpGaD
Ticlopidine—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000319	0.0054	CcSEcCtD
Ticlopidine—Osteoarthritis—Epirubicin—bone cancer	0.000319	0.0054	CcSEcCtD
Ticlopidine—Myalgia—Cisplatin—bone cancer	0.000318	0.00539	CcSEcCtD
Ticlopidine—Liver function test abnormal—Methotrexate—bone cancer	0.000315	0.00533	CcSEcCtD
Ticlopidine—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000313	0.00529	CcSEcCtD
Ticlopidine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000307	0.00488	CbGpPWpGaD
Ticlopidine—Purpura—Doxorubicin—bone cancer	0.000306	0.00518	CcSEcCtD
Ticlopidine—Anaphylactic shock—Cisplatin—bone cancer	0.000305	0.00517	CcSEcCtD
Ticlopidine—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000304	0.00484	CbGpPWpGaD
Ticlopidine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000303	0.00483	CbGpPWpGaD
Ticlopidine—Thrombocytopenia—Cisplatin—bone cancer	0.000299	0.00506	CcSEcCtD
Ticlopidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000297	0.00473	CbGpPWpGaD
Ticlopidine—Hyponatraemia—Doxorubicin—bone cancer	0.000296	0.00502	CcSEcCtD
Ticlopidine—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000295	0.005	CcSEcCtD
Ticlopidine—Osteoarthritis—Doxorubicin—bone cancer	0.000295	0.005	CcSEcCtD
Ticlopidine—Liver function test abnormal—Epirubicin—bone cancer	0.000294	0.00498	CcSEcCtD
Ticlopidine—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000294	0.00468	CbGpPWpGaD
Ticlopidine—Eosinophilia—Methotrexate—bone cancer	0.000292	0.00494	CcSEcCtD
Ticlopidine—Anorexia—Cisplatin—bone cancer	0.000291	0.00493	CcSEcCtD
Ticlopidine—P2RY12—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00029	0.00462	CbGpPWpGaD
Ticlopidine—P2RY12—GPCR ligand binding—GRM1—bone cancer	0.000286	0.00455	CbGpPWpGaD
Ticlopidine—Pancytopenia—Methotrexate—bone cancer	0.00028	0.00474	CcSEcCtD
Ticlopidine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000278	0.00471	CcSEcCtD
Ticlopidine—Abdominal distension—Epirubicin—bone cancer	0.000277	0.0047	CcSEcCtD
Ticlopidine—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000277	0.00441	CbGpPWpGaD
Ticlopidine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000277	0.0044	CbGpPWpGaD
Ticlopidine—Eosinophilia—Epirubicin—bone cancer	0.000273	0.00462	CcSEcCtD
Ticlopidine—Liver function test abnormal—Doxorubicin—bone cancer	0.000272	0.00461	CcSEcCtD
Ticlopidine—Decreased appetite—Cisplatin—bone cancer	0.000265	0.00449	CcSEcCtD
Ticlopidine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000263	0.00419	CbGpPWpGaD
Ticlopidine—MPO—C-MYB transcription factor network—PTGS2—bone cancer	0.000263	0.00419	CbGpPWpGaD
Ticlopidine—Pancytopenia—Epirubicin—bone cancer	0.000262	0.00443	CcSEcCtD
Ticlopidine—Pain—Cisplatin—bone cancer	0.000261	0.00442	CcSEcCtD
Ticlopidine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00026	0.00441	CcSEcCtD
Ticlopidine—Renal failure—Methotrexate—bone cancer	0.000258	0.00437	CcSEcCtD
Ticlopidine—Abdominal distension—Doxorubicin—bone cancer	0.000257	0.00435	CcSEcCtD
Ticlopidine—MPO—Selenium Micronutrient Network—PTGS2—bone cancer	0.000254	0.00403	CbGpPWpGaD
Ticlopidine—Eosinophilia—Doxorubicin—bone cancer	0.000252	0.00427	CcSEcCtD
Ticlopidine—Haematuria—Methotrexate—bone cancer	0.00025	0.00424	CcSEcCtD
Ticlopidine—Epistaxis—Methotrexate—bone cancer	0.000248	0.00419	CcSEcCtD
Ticlopidine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000244	0.00412	CcSEcCtD
Ticlopidine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000243	0.00386	CbGpPWpGaD
Ticlopidine—Pancytopenia—Doxorubicin—bone cancer	0.000242	0.0041	CcSEcCtD
Ticlopidine—Renal failure—Epirubicin—bone cancer	0.000242	0.00409	CcSEcCtD
Ticlopidine—Body temperature increased—Cisplatin—bone cancer	0.000241	0.00408	CcSEcCtD
Ticlopidine—Neuropathy peripheral—Epirubicin—bone cancer	0.000241	0.00408	CcSEcCtD
Ticlopidine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00024	0.00381	CbGpPWpGaD
Ticlopidine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000238	0.00378	CbGpPWpGaD
Ticlopidine—Haemoglobin—Methotrexate—bone cancer	0.000237	0.00401	CcSEcCtD
Ticlopidine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000237	0.00377	CbGpPWpGaD
Ticlopidine—Haemorrhage—Methotrexate—bone cancer	0.000236	0.00399	CcSEcCtD
Ticlopidine—Hepatitis—Methotrexate—bone cancer	0.000236	0.00399	CcSEcCtD
Ticlopidine—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000235	0.00373	CbGpPWpGaD
Ticlopidine—Haematuria—Epirubicin—bone cancer	0.000234	0.00397	CcSEcCtD
Ticlopidine—Epistaxis—Epirubicin—bone cancer	0.000232	0.00392	CcSEcCtD
Ticlopidine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000225	0.00382	CcSEcCtD
Ticlopidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000225	0.00358	CbGpPWpGaD
Ticlopidine—Hypersensitivity—Cisplatin—bone cancer	0.000225	0.00381	CcSEcCtD
Ticlopidine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000224	0.00357	CbGpPWpGaD
Ticlopidine—Renal failure—Doxorubicin—bone cancer	0.000223	0.00378	CcSEcCtD
Ticlopidine—Erythema multiforme—Methotrexate—bone cancer	0.000223	0.00377	CcSEcCtD
Ticlopidine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000223	0.00377	CcSEcCtD
Ticlopidine—Haemoglobin—Epirubicin—bone cancer	0.000222	0.00375	CcSEcCtD
Ticlopidine—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000221	0.00352	CbGpPWpGaD
Ticlopidine—Hepatitis—Epirubicin—bone cancer	0.000221	0.00373	CcSEcCtD
Ticlopidine—Haemorrhage—Epirubicin—bone cancer	0.000221	0.00373	CcSEcCtD
Ticlopidine—Tinnitus—Methotrexate—bone cancer	0.00022	0.00372	CcSEcCtD
Ticlopidine—Asthenia—Cisplatin—bone cancer	0.000219	0.00371	CcSEcCtD
Ticlopidine—Haematuria—Doxorubicin—bone cancer	0.000217	0.00367	CcSEcCtD
Ticlopidine—Epistaxis—Doxorubicin—bone cancer	0.000214	0.00363	CcSEcCtD
Ticlopidine—Diarrhoea—Cisplatin—bone cancer	0.000209	0.00354	CcSEcCtD
Ticlopidine—Erythema multiforme—Epirubicin—bone cancer	0.000209	0.00353	CcSEcCtD
Ticlopidine—Tinnitus—Epirubicin—bone cancer	0.000206	0.00348	CcSEcCtD
Ticlopidine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000205	0.00327	CbGpPWpGaD
Ticlopidine—Haemoglobin—Doxorubicin—bone cancer	0.000205	0.00347	CcSEcCtD
Ticlopidine—Hepatitis—Doxorubicin—bone cancer	0.000204	0.00346	CcSEcCtD
Ticlopidine—Haemorrhage—Doxorubicin—bone cancer	0.000204	0.00346	CcSEcCtD
Ticlopidine—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000203	0.00323	CbGpPWpGaD
Ticlopidine—P2RY12—GPCR ligand binding—SMO—bone cancer	0.000202	0.00321	CbGpPWpGaD
Ticlopidine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000197	0.00313	CbGpPWpGaD
Ticlopidine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000194	0.00309	CbGpPWpGaD
Ticlopidine—Vomiting—Cisplatin—bone cancer	0.000194	0.00329	CcSEcCtD
Ticlopidine—Erythema multiforme—Doxorubicin—bone cancer	0.000193	0.00327	CcSEcCtD
Ticlopidine—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000193	0.00307	CbGpPWpGaD
Ticlopidine—Rash—Cisplatin—bone cancer	0.000192	0.00326	CcSEcCtD
Ticlopidine—Dermatitis—Cisplatin—bone cancer	0.000192	0.00325	CcSEcCtD
Ticlopidine—Tinnitus—Doxorubicin—bone cancer	0.00019	0.00322	CcSEcCtD
Ticlopidine—MPO—Folate Metabolism—TP53—bone cancer	0.00019	0.00302	CbGpPWpGaD
Ticlopidine—Flatulence—Epirubicin—bone cancer	0.000189	0.0032	CcSEcCtD
Ticlopidine—P2RY12—GPCR downstream signaling—RGS1—bone cancer	0.000187	0.00297	CbGpPWpGaD
Ticlopidine—P2RY12—GPCR downstream signaling—GRM4—bone cancer	0.000187	0.00297	CbGpPWpGaD
Ticlopidine—Muscle spasms—Epirubicin—bone cancer	0.000185	0.00313	CcSEcCtD
Ticlopidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000183	0.00292	CbGpPWpGaD
Ticlopidine—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000182	0.00289	CbGpPWpGaD
Ticlopidine—Nausea—Cisplatin—bone cancer	0.000181	0.00307	CcSEcCtD
Ticlopidine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000181	0.00288	CbGpPWpGaD
Ticlopidine—P2RY12—Hemostasis—SPARC—bone cancer	0.00018	0.00287	CbGpPWpGaD
Ticlopidine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000177	0.00281	CbGpPWpGaD
Ticlopidine—Flatulence—Doxorubicin—bone cancer	0.000175	0.00296	CcSEcCtD
Ticlopidine—Myalgia—Methotrexate—bone cancer	0.000175	0.00296	CcSEcCtD
Ticlopidine—Arthralgia—Methotrexate—bone cancer	0.000175	0.00296	CcSEcCtD
Ticlopidine—Muscle spasms—Doxorubicin—bone cancer	0.000171	0.00289	CcSEcCtD
Ticlopidine—P2RY12—Signaling by GPCR—RGS1—bone cancer	0.000169	0.0027	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling by GPCR—GRM4—bone cancer	0.000169	0.0027	CbGpPWpGaD
Ticlopidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000169	0.00268	CbGpPWpGaD
Ticlopidine—Anaphylactic shock—Methotrexate—bone cancer	0.000167	0.00284	CcSEcCtD
Ticlopidine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000167	0.00266	CbGpPWpGaD
Ticlopidine—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000167	0.00265	CbGpPWpGaD
Ticlopidine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000166	0.00265	CbGpPWpGaD
Ticlopidine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000165	0.00263	CbGpPWpGaD
Ticlopidine—P2RY12—Hemostasis—GNA11—bone cancer	0.000165	0.00262	CbGpPWpGaD
Ticlopidine—Thrombocytopenia—Methotrexate—bone cancer	0.000164	0.00278	CcSEcCtD
Ticlopidine—Arthralgia—Epirubicin—bone cancer	0.000163	0.00277	CcSEcCtD
Ticlopidine—Myalgia—Epirubicin—bone cancer	0.000163	0.00277	CcSEcCtD
Ticlopidine—P2RY12—GPCR downstream signaling—GRM1—bone cancer	0.000162	0.00257	CbGpPWpGaD
Ticlopidine—Anorexia—Methotrexate—bone cancer	0.00016	0.0027	CcSEcCtD
Ticlopidine—Anaphylactic shock—Epirubicin—bone cancer	0.000157	0.00265	CcSEcCtD
Ticlopidine—Thrombocytopenia—Epirubicin—bone cancer	0.000153	0.0026	CcSEcCtD
Ticlopidine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000153	0.00258	CcSEcCtD
Ticlopidine—Arthralgia—Doxorubicin—bone cancer	0.000151	0.00256	CcSEcCtD
Ticlopidine—Myalgia—Doxorubicin—bone cancer	0.000151	0.00256	CcSEcCtD
Ticlopidine—P2RY12—Hemostasis—IL3—bone cancer	0.000149	0.00238	CbGpPWpGaD
Ticlopidine—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000149	0.00238	CbGpPWpGaD
Ticlopidine—Anorexia—Epirubicin—bone cancer	0.000149	0.00253	CcSEcCtD
Ticlopidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000149	0.00237	CbGpPWpGaD
Ticlopidine—Dyspepsia—Methotrexate—bone cancer	0.000147	0.0025	CcSEcCtD
Ticlopidine—P2RY12—Signaling by GPCR—GRM1—bone cancer	0.000147	0.00234	CbGpPWpGaD
Ticlopidine—Decreased appetite—Methotrexate—bone cancer	0.000146	0.00246	CcSEcCtD
Ticlopidine—Anaphylactic shock—Doxorubicin—bone cancer	0.000145	0.00246	CcSEcCtD
Ticlopidine—Pain—Methotrexate—bone cancer	0.000143	0.00242	CcSEcCtD
Ticlopidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000143	0.00227	CbGpPWpGaD
Ticlopidine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000143	0.00242	CcSEcCtD
Ticlopidine—Thrombocytopenia—Doxorubicin—bone cancer	0.000142	0.0024	CcSEcCtD
Ticlopidine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000141	0.00224	CbGpPWpGaD
Ticlopidine—Anorexia—Doxorubicin—bone cancer	0.000138	0.00234	CcSEcCtD
Ticlopidine—Dyspepsia—Epirubicin—bone cancer	0.000138	0.00234	CcSEcCtD
Ticlopidine—Gastrointestinal pain—Methotrexate—bone cancer	0.000137	0.00232	CcSEcCtD
Ticlopidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000137	0.00218	CbGpPWpGaD
Ticlopidine—Decreased appetite—Epirubicin—bone cancer	0.000136	0.00231	CcSEcCtD
Ticlopidine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000136	0.00216	CbGpPWpGaD
Ticlopidine—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000135	0.00215	CbGpPWpGaD
Ticlopidine—Pain—Epirubicin—bone cancer	0.000134	0.00227	CcSEcCtD
Ticlopidine—Urticaria—Methotrexate—bone cancer	0.000133	0.00225	CcSEcCtD
Ticlopidine—Body temperature increased—Methotrexate—bone cancer	0.000132	0.00224	CcSEcCtD
Ticlopidine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000132	0.00224	CcSEcCtD
Ticlopidine—Gastrointestinal pain—Epirubicin—bone cancer	0.000128	0.00217	CcSEcCtD
Ticlopidine—Dyspepsia—Doxorubicin—bone cancer	0.000128	0.00216	CcSEcCtD
Ticlopidine—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000127	0.00203	CbGpPWpGaD
Ticlopidine—Decreased appetite—Doxorubicin—bone cancer	0.000126	0.00213	CcSEcCtD
Ticlopidine—Urticaria—Epirubicin—bone cancer	0.000125	0.00211	CcSEcCtD
Ticlopidine—Pain—Doxorubicin—bone cancer	0.000124	0.0021	CcSEcCtD
Ticlopidine—Body temperature increased—Epirubicin—bone cancer	0.000124	0.0021	CcSEcCtD
Ticlopidine—Hypersensitivity—Methotrexate—bone cancer	0.000123	0.00209	CcSEcCtD
Ticlopidine—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000123	0.00195	CbGpPWpGaD
Ticlopidine—Asthenia—Methotrexate—bone cancer	0.00012	0.00203	CcSEcCtD
Ticlopidine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000119	0.00201	CcSEcCtD
Ticlopidine—Pruritus—Methotrexate—bone cancer	0.000118	0.00201	CcSEcCtD
Ticlopidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000116	0.00184	CbGpPWpGaD
Ticlopidine—Hypersensitivity—Epirubicin—bone cancer	0.000115	0.00195	CcSEcCtD
Ticlopidine—Urticaria—Doxorubicin—bone cancer	0.000115	0.00195	CcSEcCtD
Ticlopidine—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000115	0.00183	CbGpPWpGaD
Ticlopidine—Body temperature increased—Doxorubicin—bone cancer	0.000115	0.00194	CcSEcCtD
Ticlopidine—Diarrhoea—Methotrexate—bone cancer	0.000115	0.00194	CcSEcCtD
Ticlopidine—Asthenia—Epirubicin—bone cancer	0.000112	0.0019	CcSEcCtD
Ticlopidine—Pruritus—Epirubicin—bone cancer	0.000111	0.00188	CcSEcCtD
Ticlopidine—Dizziness—Methotrexate—bone cancer	0.000111	0.00188	CcSEcCtD
Ticlopidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000111	0.00176	CbGpPWpGaD
Ticlopidine—Diarrhoea—Epirubicin—bone cancer	0.000107	0.00182	CcSEcCtD
Ticlopidine—Hypersensitivity—Doxorubicin—bone cancer	0.000107	0.00181	CcSEcCtD
Ticlopidine—Vomiting—Methotrexate—bone cancer	0.000106	0.0018	CcSEcCtD
Ticlopidine—Rash—Methotrexate—bone cancer	0.000106	0.00179	CcSEcCtD
Ticlopidine—Dermatitis—Methotrexate—bone cancer	0.000105	0.00179	CcSEcCtD
Ticlopidine—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000105	0.00168	CbGpPWpGaD
Ticlopidine—Headache—Methotrexate—bone cancer	0.000105	0.00178	CcSEcCtD
Ticlopidine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000105	0.00166	CbGpPWpGaD
Ticlopidine—P2RY12—GPCR downstream signaling—GNA11—bone cancer	0.000104	0.00166	CbGpPWpGaD
Ticlopidine—Asthenia—Doxorubicin—bone cancer	0.000104	0.00176	CcSEcCtD
Ticlopidine—Dizziness—Epirubicin—bone cancer	0.000104	0.00175	CcSEcCtD
Ticlopidine—P2RY12—Signaling by GPCR—SMO—bone cancer	0.000103	0.00165	CbGpPWpGaD
Ticlopidine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000103	0.00164	CbGpPWpGaD
Ticlopidine—Pruritus—Doxorubicin—bone cancer	0.000103	0.00174	CcSEcCtD
Ticlopidine—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000102	0.00163	CbGpPWpGaD
Ticlopidine—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000101	0.00161	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—GRM4—bone cancer	0.0001	0.00159	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—RGS1—bone cancer	0.0001	0.00159	CbGpPWpGaD
Ticlopidine—Vomiting—Epirubicin—bone cancer	9.96e-05	0.00169	CcSEcCtD
Ticlopidine—Nausea—Methotrexate—bone cancer	9.95e-05	0.00168	CcSEcCtD
Ticlopidine—Diarrhoea—Doxorubicin—bone cancer	9.92e-05	0.00168	CcSEcCtD
Ticlopidine—Rash—Epirubicin—bone cancer	9.88e-05	0.00167	CcSEcCtD
Ticlopidine—Dermatitis—Epirubicin—bone cancer	9.87e-05	0.00167	CcSEcCtD
Ticlopidine—Headache—Epirubicin—bone cancer	9.82e-05	0.00166	CcSEcCtD
Ticlopidine—P2RY12—Hemostasis—PLAU—bone cancer	9.81e-05	0.00156	CbGpPWpGaD
Ticlopidine—CYP1A1—Biological oxidations—CYP3A4—bone cancer	9.65e-05	0.00154	CbGpPWpGaD
Ticlopidine—Dizziness—Doxorubicin—bone cancer	9.59e-05	0.00162	CcSEcCtD
Ticlopidine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	9.53e-05	0.00152	CbGpPWpGaD
Ticlopidine—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	9.52e-05	0.00151	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling by GPCR—GNA11—bone cancer	9.46e-05	0.00151	CbGpPWpGaD
Ticlopidine—P2RY12—GPCR downstream signaling—IL3—bone cancer	9.45e-05	0.0015	CbGpPWpGaD
Ticlopidine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	9.4e-05	0.0015	CbGpPWpGaD
Ticlopidine—Nausea—Epirubicin—bone cancer	9.31e-05	0.00158	CcSEcCtD
Ticlopidine—Vomiting—Doxorubicin—bone cancer	9.22e-05	0.00156	CcSEcCtD
Ticlopidine—Rash—Doxorubicin—bone cancer	9.14e-05	0.00155	CcSEcCtD
Ticlopidine—Dermatitis—Doxorubicin—bone cancer	9.13e-05	0.00155	CcSEcCtD
Ticlopidine—Headache—Doxorubicin—bone cancer	9.08e-05	0.00154	CcSEcCtD
Ticlopidine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	9e-05	0.00143	CbGpPWpGaD
Ticlopidine—CYP2B6—Biological oxidations—GSTP1—bone cancer	8.94e-05	0.00142	CbGpPWpGaD
Ticlopidine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	8.85e-05	0.00141	CbGpPWpGaD
Ticlopidine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	8.82e-05	0.0014	CbGpPWpGaD
Ticlopidine—CYP2E1—Biological oxidations—GSTP1—bone cancer	8.75e-05	0.00139	CbGpPWpGaD
Ticlopidine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	8.73e-05	0.00139	CbGpPWpGaD
Ticlopidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	8.71e-05	0.00139	CbGpPWpGaD
Ticlopidine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	8.71e-05	0.00139	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—GRM1—bone cancer	8.68e-05	0.00138	CbGpPWpGaD
Ticlopidine—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	8.63e-05	0.00137	CbGpPWpGaD
Ticlopidine—Nausea—Doxorubicin—bone cancer	8.61e-05	0.00146	CcSEcCtD
Ticlopidine—P2RY12—Signaling by GPCR—IL3—bone cancer	8.58e-05	0.00137	CbGpPWpGaD
Ticlopidine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.57e-05	0.00136	CbGpPWpGaD
Ticlopidine—CYP1A1—Biological oxidations—GSTP1—bone cancer	8.25e-05	0.00131	CbGpPWpGaD
Ticlopidine—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	8.14e-05	0.0013	CbGpPWpGaD
Ticlopidine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	8.12e-05	0.00129	CbGpPWpGaD
Ticlopidine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	7.9e-05	0.00126	CbGpPWpGaD
Ticlopidine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	7.83e-05	0.00125	CbGpPWpGaD
Ticlopidine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	7.79e-05	0.00124	CbGpPWpGaD
Ticlopidine—CYP2C8—Biological oxidations—GSTP1—bone cancer	7.57e-05	0.0012	CbGpPWpGaD
Ticlopidine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	7.46e-05	0.00119	CbGpPWpGaD
Ticlopidine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	7.33e-05	0.00117	CbGpPWpGaD
Ticlopidine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	7.26e-05	0.00116	CbGpPWpGaD
Ticlopidine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.2e-05	0.00115	CbGpPWpGaD
Ticlopidine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	7.16e-05	0.00114	CbGpPWpGaD
Ticlopidine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.1e-05	0.00113	CbGpPWpGaD
Ticlopidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.06e-05	0.00112	CbGpPWpGaD
Ticlopidine—CYP2C19—Biological oxidations—GSTP1—bone cancer	6.75e-05	0.00108	CbGpPWpGaD
Ticlopidine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	6.66e-05	0.00106	CbGpPWpGaD
Ticlopidine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.27e-05	0.000998	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—NDUFA12—bone cancer	6.26e-05	0.000997	CbGpPWpGaD
Ticlopidine—CYP2D6—Biological oxidations—GSTP1—bone cancer	6.21e-05	0.000989	CbGpPWpGaD
Ticlopidine—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.16e-05	0.00098	CbGpPWpGaD
Ticlopidine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.15e-05	0.000979	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—NDUFA12—bone cancer	6.14e-05	0.000977	CbGpPWpGaD
Ticlopidine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	6.13e-05	0.000975	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—SMO—bone cancer	6.11e-05	0.000973	CbGpPWpGaD
Ticlopidine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.07e-05	0.000967	CbGpPWpGaD
Ticlopidine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.07e-05	0.000966	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—NDUFA12—bone cancer	5.78e-05	0.000921	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—GNA11—bone cancer	5.59e-05	0.00089	CbGpPWpGaD
Ticlopidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.55e-05	0.000884	CbGpPWpGaD
Ticlopidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.55e-05	0.000884	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—NDUFA12—bone cancer	5.3e-05	0.000844	CbGpPWpGaD
Ticlopidine—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.26e-05	0.000838	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—ATF1—bone cancer	5.2e-05	0.000827	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—NT5C3A—bone cancer	5.19e-05	0.000826	CbGpPWpGaD
Ticlopidine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.19e-05	0.000826	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—NT5C3A—bone cancer	5.08e-05	0.000809	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—IL3—bone cancer	5.07e-05	0.000807	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—NT5C3A—bone cancer	4.79e-05	0.000763	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—NDUFA12—bone cancer	4.73e-05	0.000753	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—NT5C3A—bone cancer	4.39e-05	0.000699	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—NDUFA12—bone cancer	4.35e-05	0.000693	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—TGFBR2—bone cancer	4.33e-05	0.00069	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—NDUFA12—bone cancer	4.32e-05	0.000687	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—IGF1R—bone cancer	4.08e-05	0.000649	CbGpPWpGaD
Ticlopidine—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.06e-05	0.000646	CbGpPWpGaD
Ticlopidine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.01e-05	0.000638	CbGpPWpGaD
Ticlopidine—P2RY12—Hemostasis—TP53—bone cancer	3.94e-05	0.000628	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—NT5C3A—bone cancer	3.92e-05	0.000624	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—NDUFA12—bone cancer	3.69e-05	0.000587	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—NT5C3A—bone cancer	3.61e-05	0.000574	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—NT5C3A—bone cancer	3.58e-05	0.000569	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—NT5C3A—bone cancer	3.06e-05	0.000486	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—KIT—bone cancer	2.96e-05	0.000471	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—NDUFA12—bone cancer	2.85e-05	0.000453	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—BRAF—bone cancer	2.78e-05	0.000443	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling by GPCR—EGFR—bone cancer	2.69e-05	0.000429	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.36e-05	0.000375	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—MDM2—bone cancer	2.33e-05	0.000371	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—ENO2—bone cancer	2.27e-05	0.000362	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—ENO2—bone cancer	2.23e-05	0.000354	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—DHFR—bone cancer	2.11e-05	0.000336	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—ENO2—bone cancer	2.1e-05	0.000334	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—DHFR—bone cancer	2.07e-05	0.000329	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—JUN—bone cancer	2.02e-05	0.000322	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—GNA11—bone cancer	1.97e-05	0.000314	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—MMP9—bone cancer	1.97e-05	0.000314	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—DHFR—bone cancer	1.95e-05	0.00031	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—GNA11—bone cancer	1.93e-05	0.000307	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—ENO2—bone cancer	1.92e-05	0.000306	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—GNA11—bone cancer	1.82e-05	0.00029	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—CYP3A4—bone cancer	1.79e-05	0.000284	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—DHFR—bone cancer	1.79e-05	0.000284	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—CYP3A4—bone cancer	1.75e-05	0.000279	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—ENO2—bone cancer	1.72e-05	0.000273	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—GNA11—bone cancer	1.67e-05	0.000266	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—CYP3A4—bone cancer	1.65e-05	0.000263	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.64e-05	0.000261	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—DHFR—bone cancer	1.59e-05	0.000254	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—EGFR—bone cancer	1.59e-05	0.000253	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—ENO2—bone cancer	1.58e-05	0.000252	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—ENO2—bone cancer	1.57e-05	0.000249	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—GSTP1—bone cancer	1.53e-05	0.000243	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—CYP3A4—bone cancer	1.51e-05	0.000241	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.51e-05	0.00024	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—GSTP1—bone cancer	1.5e-05	0.000238	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—GNA11—bone cancer	1.49e-05	0.000237	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—DHFR—bone cancer	1.47e-05	0.000233	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—DHFR—bone cancer	1.45e-05	0.000231	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—GSTP1—bone cancer	1.41e-05	0.000225	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—GNA11—bone cancer	1.37e-05	0.000218	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—GNA11—bone cancer	1.36e-05	0.000216	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.35e-05	0.000215	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.34e-05	0.000214	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—ENO2—bone cancer	1.34e-05	0.000213	CbGpPWpGaD
Ticlopidine—P2RY12—Signaling Pathways—TP53—bone cancer	1.34e-05	0.000213	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—GSTP1—bone cancer	1.29e-05	0.000206	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.24e-05	0.000198	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—DHFR—bone cancer	1.24e-05	0.000198	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—CYP3A4—bone cancer	1.23e-05	0.000196	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.23e-05	0.000195	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—GNA11—bone cancer	1.16e-05	0.000185	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—GSTP1—bone cancer	1.16e-05	0.000184	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—GSTP1—bone cancer	1.06e-05	0.000169	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—GSTP1—bone cancer	1.05e-05	0.000168	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.05e-05	0.000167	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.05e-05	0.000167	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—ENO2—bone cancer	1.03e-05	0.000164	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—DHFR—bone cancer	9.59e-06	0.000153	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—GSTP1—bone cancer	9e-06	0.000143	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—GNA11—bone cancer	8.96e-06	0.000143	CbGpPWpGaD
Ticlopidine—CYP2B6—Metabolism—PTGS2—bone cancer	7.92e-06	0.000126	CbGpPWpGaD
Ticlopidine—CYP2E1—Metabolism—PTGS2—bone cancer	7.76e-06	0.000123	CbGpPWpGaD
Ticlopidine—CYP1A1—Metabolism—PTGS2—bone cancer	7.31e-06	0.000116	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—GSTP1—bone cancer	6.95e-06	0.000111	CbGpPWpGaD
Ticlopidine—CYP2C8—Metabolism—PTGS2—bone cancer	6.7e-06	0.000107	CbGpPWpGaD
Ticlopidine—CYP2C19—Metabolism—PTGS2—bone cancer	5.98e-06	9.52e-05	CbGpPWpGaD
Ticlopidine—CYP2D6—Metabolism—PTGS2—bone cancer	5.5e-06	8.76e-05	CbGpPWpGaD
Ticlopidine—CYP2C9—Metabolism—PTGS2—bone cancer	5.46e-06	8.68e-05	CbGpPWpGaD
Ticlopidine—CYP1A2—Metabolism—PTGS2—bone cancer	4.66e-06	7.42e-05	CbGpPWpGaD
Ticlopidine—CYP3A4—Metabolism—PTGS2—bone cancer	3.6e-06	5.73e-05	CbGpPWpGaD
